Award Amount:Up to $600,000 based on stage and scope of research, for one year Application Due Date: Letter of Intent Due October 9, 2020
Additional Information - The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Specifically, this RFP focuses on: - Developing novel PET ligands for clinical use - Supporting novel CSF biomarkers - Validating established MRI approaches in larger cohorts - Peripheral biofluids and digital approaches are supported through the Diagnostics Accelerator RFP.
Novel biomarkers of neuroinflammation and synaptic integrity are considered high-priority. Other target areas of interest include: - Neuronal loss - Vascular injury and blood-brain barrier integrity - Mitochondria and metabolic function - Protein misfolding/proteostasis - Oxidative stress - White matter changes - Other novel targets supported by compelling biological rationale and connection to the disease
The Alzheimer's Drug Discovery Foundation has limited interest in CSF measures of amyloid and tau.